Squamous cell carcinoma of the bladder: poor response to neoadjuvant chemotherapy
Autor: | Sameer Siddiqui, Facundo Davaro, Aaron Dotson, Syed Johar Raza, Allison May, Zachary Hamilton |
---|---|
Rok vydání: | 2019 |
Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty medicine.medical_treatment Malignancy Cystectomy 03 medical and health sciences 0302 clinical medicine Surgical oncology Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Stage (cooking) Survival analysis Aged Carcinoma Transitional Cell Chemotherapy Bladder cancer business.industry Proportional hazards model Hematology General Medicine Prognosis medicine.disease Neoadjuvant Therapy Survival Rate 030104 developmental biology Urinary Bladder Neoplasms 030220 oncology & carcinogenesis Carcinoma Squamous Cell Female Surgery business |
Zdroj: | International Journal of Clinical Oncology. 24:706-711 |
ISSN: | 1437-7772 1341-9625 |
DOI: | 10.1007/s10147-019-01409-x |
Popis: | Squamous cell carcinoma (SCC) of the bladder is a rare, aggressive malignancy. Unlike urothelial cell carcinoma, SCC is resistant to chemotherapy and guidelines recommend radical cystectomy (RC) without neoadjuvant chemotherapy (NAC). We aimed to evaluate the current management and survival of patients with invasive SCC treated with or without NAC. 671 patients with invasive SCC bladder cancer from 2004 to 2015 in the National Cancer Data Base were identified. Patients were stratified by treatment with RC alone or NAC prior to RC (NAC + RC). Survival analysis was performed with Kaplan–Meier and Cox regression. Secondary outcomes included length of stay and readmission. Of 671 patients, 92.8% were treated with RC alone and 7.2% with NAC + RC. Cox regression for mortality was performed including age, Charlson score, clinical stage, and NAC. Increased risk of mortality was noted with increasing age (OR 1.01, p = 0.023) and Charlson score of 1–3 (HR 1.58–1.68, p |
Databáze: | OpenAIRE |
Externí odkaz: |